‘It is encouraging’: Sotyktu sails through phase 3 trial in psoriatic arthritis
Sotyktu significantly outperformed placebo for the treatment of psoriatic arthritis in a phase 3 trial, meeting key endpoints at 16 weeks, according to late-breaking data presented at the American Academy of Dermatology annual meeting. The drug — a first-in-class oral, selective, allosteric TYK2 inhibitor currently approved in plaque psoriasis — fills an unmet need for a novel